CD274 and cancer: Thus, the current systemic ICI immunotherapy injecting anti-PD1 or anti-PD-L1 antibodies may not be effective to activate anti-cancer immunity of HCC nor to elicit durable clinical benefit in HCC [37,38,42,43].